Colchicine, Dependence, ICH - Intracerebral Hemorrhage, Stroke
Conditions
Brief summary
Data indicate that patients with intracerebral hemorrhage (ICH) are at high risk for thromboembolic events and disability that is not being sufficiently mitigated by current treatment strategies. This is aggravated by the cessation of antithrombotic medications for significant periods after hemorrhage. These findings highlight the need for novel treatments that modify the high risk for major vascular events and functional outcomes in ICH survivors. The objective of CoVasc-ICH 2 is to demonstrate that oral colchicine 0.5 mg daily is superior to placebo for improving the outcomes of ICH survivors with evidence or risk factors for atherosclerosis, when started within 72 hours from ICH onset.
Interventions
DRUGColchicine 0.5 MG
colchicine 0.5mg once-daily
DRUGPlacebo
matching placebo, lacking active ingredient, once-daily
Sponsors
Population Health Research Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Double-blind
Intervention model description
Double-blind, randomized, placebo-controlled, phase III study
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Adult patients presenting with spontaneous intraparenchymal hemorrhage within 72 hours of symptom onset and qualifying for at least one of the following categories: i. history of symptomatic coronary, peripheral and/or carotid artery disease (severe atherosclerotic vascular disease), or ii. visualized extracranial cervical/intracranial atherosclerotic disease causing any degree of stenosis/occlusion or presence of aortic arch plaque with maximum thickness ≥1 mm (moderate atherosclerotic vascular disease), or iii. two or more risk factors including: age 60 years or older, hypertension, dyslipidemia, diabetes mellitus, chronic kidney disease (eGFR: 15-50mL/min), history of ischemic stroke or current smoking (mild atherosclerotic vascular disease).
Exclusion criteria
* secondary causes of ICH (such as trauma, macrovascular anomalies, neoplasms or bleeding diathesis) * ICH volume more than 60ml in the last imaging scan prior to consent * Glasgow Coma Scale (GCS) score less than 7 or being intubated at the time of consent * inflammatory bowel disease or chronic diarrhea * cirrhosis or severe hepatic dysfunction * renal insufficiency (eGFR\<15mL/min) * concurrent or planned treatment with strong CYP3A4 inhibitors (atazanavir, clarithromycin, darunavir/ritonavir, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, tipranavir/ritonavir) or P-gp inhibitors (cyclosporine, ranolazine) * pregnancy or breast-feeding * known allergy or sensitivity to colchicine * a strong indication for colchicine where assignment to placebo is deemed unacceptable * estimated life expectancy less than 6 months at the time of enrollment, and * inability to adhere to study procedures
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy: MACE and Dependency | through study completion, an average of 36 months | Treatment with colchicine will reduce the risk for major adverse cardiovascular events (MACE) and dependency |
| Safety: Symptomatic hematoma expansion, major gastrointestinal adverse reactions or infection rates | through study completion, an average of 36 months | There will be no clinically-important change in symptomatic hematoma expansion, major gastrointestinal adverse reactions or infection rates with oral colchicine 0.5mg OD compared with matching placebo |
Contacts
CONTACTKevin W Reeh, MSc
CONTACTAmanda Taylor, BSc
PRINCIPAL_INVESTIGATORAristeidis Katsanos, MD
Population Health Research Institute, Hamilton Health Sciences, McMaster University
PRINCIPAL_INVESTIGATORAshkan Shoamanesh, MD
Population Health Research Institute, Hamilton Health Sciences, McMaster University
Outcome results
None listed